Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47
JUN 24, 202542 MIN
Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47
JUN 24, 202542 MIN
Description
<p>Joining us on this episode is <strong>Tom Neyarapally</strong>, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.</p><p><a href="https://www.genialis.com/2025/06/24/a-new-paradigm-for-generative-ai-drug-discovery-more-accurate-shots-on-a-much-wider-goal-tpm-podcast-47/" target="_blank" rel="noopener noreferer">TPM E47 highlights ></a></p><p>Episode 47 links:</p><ul><li><a href="https://www.archetypetx.com/">Archetype Therapeutics</a></li><li><a href="https://www.linkedin.com/in/tom-neyarapally-8786b7/">Tom Neyarapally on LinkedIn </a></li><li><a href="https://www.linkedin.com/pulse/exploring-patient-first-path-drug-discovery-tom-neyarapally-fx6ze/?trackingId=TdgneQVoSKaFdfG0g0VUkw%3D%3D">“Exploring a “Patient-First” Path in Drug Discovery”</a>, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten</li></ul>
